Please note

Due to the recent spike in Covid-19 cases, we are no longer able to entertain walk-in visits to our headquarters or any of our facilities.

Vinorelbine Tartrate 10mg / ml injection

Ferron Par Pharmaceuticals

Ingredients in every ml

Vinorelbine Tartrate 10 mg

Each package contains

1 vial of 1 ml

Dosage form

injection

Dosage formInjection

Flavour

None

W.H.O. classification

L01C
L01C

A.T.C. Level 1

Anatomical Main group

L - Antineoplastic and immunomodulating agents
L01C

A.T.C. Level 2

Therapeutic subgroup

L01 - Antineoplastic Agents
L01C

A.T.C. Level 3

Pharmacological subgroup

L01C - Plant Alkaloids and Other Natural Products; Antineoplastic Drugs

Available in

Indonesia

Warnings

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

CAUTIONThis item may not be safe for use while operating heavy machinery. Use with caution and after consultation with your doctor.

Pregnancy

NOT RECOMMENDEDThis item is not safe for use during pregnancy.

Lactation

NOT RECOMMENDEDThis item is not safe for use during lactation.

Indication

Treatment of Non-Small-Cell lung cancer and advanced breast cancer in combination with standard chemotherapy.

Dosage

FOR ALL AGES
Strictly by intravenous administration after appropriate dilution. The use of intrathecal route is contraindicated. It is recommended to infuse vinorelbine over 6-10 minutes after dilution in 20-50 ml of 0.9% NaCl Injection (normal saline solution) or 5% dextrose solution. Administration should always be followed with at least 250 ml of an isotonic solution infusion to flush the vein.

— In monotherapy:
The usual dose given is 25-30 mg/m² once weekly.

— In combination chemotherapy:
The dose may be the same while the frequency of administration reduced, i.e.: day 1 and 5 every 3 weeks or day 1 and 8 every 3 weeks according to treatment protocol.

PATIENTS WITH RENAL INSUFFICIENCY
No dose adjustments are required for renal insufficiency. If moderate or severe neurotoxicity develops, vinorelbine should be discontinued. The dosage should be adjusted according to hematologic toxicity or hepatic insufficiency, whichever results the lower dose.